{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:26:25Z","timestamp":1788827185598,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2022YFC2304102"],"award-info":[{"award-number":["2022YFC2304102"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDB0490000"],"award-info":[{"award-number":["XDB0490000"]}]},{"name":"USTC Research Funds of the Double First-Class Initiative","award":["YD9100002040"],"award-info":[{"award-number":["YD9100002040"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04557-1","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:05:14Z","timestamp":1779768314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circular RNA vaccines encoding fusion proteins of Mpox Virus A35R-M1R and B6R-A29L induce robust and durable protective immunity in mice"],"prefix":"10.1186","volume":"24","author":[{"given":"Xia","family":"Chuai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinge","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"4557_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","volume":"242","author":"J Whitley","year":"2022","unstructured":"Whitley J, Zwolinski C, Denis C, Maughan M, Hayles L, Clarke D, Snare M, Liao H, Chiou S, Marmura T, et al. Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Transl Res. 2022;242:38\u201355.","journal-title":"Transl Res"},{"key":"4557_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021;20:33.","journal-title":"Mol Cancer"},{"key":"4557_CR3","doi-asserted-by":"crossref","unstructured":"Uddin MN, Roni MA. Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. Vaccines (Basel). 2021;9:1033.","DOI":"10.3390\/vaccines9091033"},{"key":"4557_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","volume":"625","author":"TE Mulroney","year":"2024","unstructured":"Mulroney TE, Poyry T, Yam-Puc JC, Rust M, Harvey RF, Kalmar L, Horner E, Booth L, Ferreira AP, Stoneley M, et al. N(1)-methylpseudouridylation of mRNA causes\u2009+\u20091 ribosomal frameshifting. Nature. 2024;625:189\u201394.","journal-title":"Nature"},{"key":"4557_CR5","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","volume":"185","author":"CX Liu","year":"2022","unstructured":"Liu CX, Chen LL. Circular RNAs: Characterization, cellular roles, and applications. Cell. 2022;185:2016\u201334.","journal-title":"Cell"},{"key":"4557_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","volume":"20","author":"LS Kristensen","year":"2019","unstructured":"Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20:675\u201391.","journal-title":"Nat Rev Genet"},{"key":"4557_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","volume":"8","author":"D Niu","year":"2023","unstructured":"Niu D, Wu Y, Lian J. Circular RNA vaccine in disease prevention and treatment. Signal Transduct Target Ther. 2023;8:341.","journal-title":"Signal Transduct Target Ther"},{"key":"4557_CR8","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H, Zhang X, Tian F, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185:1728\u2013e17441716.","journal-title":"Cell"},{"key":"4557_CR9","doi-asserted-by":"publisher","first-page":"105370","DOI":"10.1016\/j.antiviral.2022.105370","volume":"204","author":"C Seephetdee","year":"2022","unstructured":"Seephetdee C, Bhukhai K, Buasri N, Leelukkanaveera P, Lerdwattanasombat P, Manopwisedjaroen S, Phueakphud N, Kuhaudomlarp S, Olmedillas E, Saphire EO, et al. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Antiviral Res. 2022;204:105370.","journal-title":"Antiviral Res"},{"key":"4557_CR10","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1021\/acsami.4c20770","volume":"17","author":"K Huang","year":"2025","unstructured":"Huang K, Li N, Li Y, Zhu J, Fan Q, Yang J, Gao Y, Liu Y, Gao S, Zhao P, et al. Circular mRNA Vaccine against SARS-COV-2 Variants Enabled by Degradable Lipid Nanoparticles. ACS Appl Mater Interfaces. 2025;17:4699\u2013710.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4557_CR11","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1038\/s41467-024-53242-0","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu X, Li Z, Li X, Wu W, Jiang H, Zheng Y, Zhou J, Ye X, Lu J, Wang W, et al. A single-dose circular RNA vaccine prevents Zika virus infection without enhancing dengue severity in mice. Nat Commun. 2024;15:8932.","journal-title":"Nat Commun"},{"key":"4557_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41541-024-00963-4","volume":"9","author":"X Yue","year":"2024","unstructured":"Yue X, Zhong C, Cao R, Liu S, Qin Z, Liu L, Zhai Y, Luo W, Lian Y, Zhang M, et al. CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice. NPJ Vaccines. 2024;9:170.","journal-title":"NPJ Vaccines"},{"key":"4557_CR13","doi-asserted-by":"publisher","first-page":"1562865","DOI":"10.3389\/fimmu.2025.1562865","volume":"16","author":"W Zhang","year":"2025","unstructured":"Zhang W, Wang L, Chu L, Ma X, Gao W, Wu Y, Qiao Y, Wang X, Zhao L, Hu H, et al. Bivalent circular RNA vaccines against porcine epidemic diarrhea virus and transmissible gastroenteritis virus. Front Immunol. 2025;16:1562865.","journal-title":"Front Immunol"},{"key":"4557_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(24)02353-5","volume":"405","author":"CG Beiras","year":"2025","unstructured":"Beiras CG, Malembi E, Escrig-Sarreta R, Ahuka S, Mbala P, Mavoko HM, Subissi L, Abecasis AB, Marks M, Mitja O. Concurrent outbreaks of mpox in Africa-an update. Lancet. 2025;405:86\u201396.","journal-title":"Lancet"},{"key":"4557_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/d41586-022-01421-8","volume":"606","author":"M Kozlov","year":"2022","unstructured":"Kozlov M. Monkeypox goes global: why scientists are on alert. Nature. 2022;606:15\u20136.","journal-title":"Nature"},{"key":"4557_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/jama.2022.12513","volume":"328","author":"JB Nuzzo","year":"2022","unstructured":"Nuzzo JB, Borio LL, Gostin LO. The WHO Declaration of Monkeypox as a Global Public Health Emergency. JAMA. 2022;328:615\u20137.","journal-title":"JAMA"},{"key":"4557_CR17","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1038\/s41591-024-03130-3","volume":"30","author":"EH Vakaniaki","year":"2024","unstructured":"Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O\u2019Toole A, Wawina-Bokalanga T, Mukadi-Bamuleka D, Amuri-Aziza A, Malyamungu-Bubala N, Mweshi-Kumbana F, Mutimbwa-Mambo L, et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat Med. 2024;30:2791\u20135.","journal-title":"Nat Med"},{"key":"4557_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.46234\/ccdcw2024.025","volume":"6","author":"X Wang","year":"2024","unstructured":"Wang X, Gu Z, Sheng S, Song R, Jin R. The Current State and Progress of Mpox Vaccine Research. China CDC Wkly. 2024;6:118\u201325.","journal-title":"China CDC Wkly"},{"key":"4557_CR19","doi-asserted-by":"publisher","first-page":"106156","DOI":"10.1016\/j.micpath.2023.106156","volume":"180","author":"MJ Saadh","year":"2023","unstructured":"Saadh MJ, Ghadimkhani T, Soltani N, Abbassioun A, Daniel Cosme Pecho R, Taha A, Jwad Kazem T, Yasamineh S, Gholizadeh O. Progress and prospects on vaccine development against monkeypox infection. Microb Pathog. 2023;180:106156.","journal-title":"Microb Pathog"},{"key":"4557_CR20","doi-asserted-by":"publisher","first-page":"102420","DOI":"10.1016\/j.eclinm.2023.102420","volume":"68","author":"V Mazzotta","year":"2024","unstructured":"Mazzotta V, Lepri AC, Matusali G, Cimini E, Piselli P, Aguglia C, Lanini S, Colavita F, Notari S, Oliva A, et al. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study. EClinicalMedicine. 2024;68:102420.","journal-title":"EClinicalMedicine"},{"key":"4557_CR21","doi-asserted-by":"publisher","first-page":"2192815","DOI":"10.1080\/22221751.2023.2192815","volume":"12","author":"RR Zhang","year":"2023","unstructured":"Zhang RR, Wang ZJ, Zhu YL, Tang W, Zhou C, Zhao SQ, Wu M, Ming T, Deng YQ, Chen Q, et al. Rational development of multicomponent mRNA vaccine candidates against mpox. Emerg Microbes Infect. 2023;12:2192815.","journal-title":"Emerg Microbes Infect"},{"key":"4557_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-023-01432-5","volume":"8","author":"Y Sang","year":"2023","unstructured":"Sang Y, Zhang Z, Liu F, Lu H, Yu C, Sun H, Long J, Cao Y, Mai J, Miao Y, et al. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. Signal Transduct Target Ther. 2023;8:172.","journal-title":"Signal Transduct Target Ther"},{"key":"4557_CR23","doi-asserted-by":"publisher","first-page":"eadg3540","DOI":"10.1126\/scitranslmed.adg3540","volume":"15","author":"AW Freyn","year":"2023","unstructured":"Freyn AW, Atyeo C, Earl PL, Americo JL, Chuang GY, Natarajan H, Frey TR, Gall JG, Moliva JI, Hunegnaw R, et al. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci Transl Med. 2023;15:eadg3540.","journal-title":"Sci Transl Med"},{"key":"4557_CR24","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.cell.2024.01.017","volume":"187","author":"A Zuiani","year":"2024","unstructured":"Zuiani A, Dulberger CL, De Silva NS, Marquette M, Lu YJ, Palowitch GM, Dokic A, Sanchez-Velazquez R, Schlatterer K, Sarkar S, et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell. 2024;187:1363\u2013e13731312.","journal-title":"Cell"},{"key":"4557_CR25","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1038\/s41467-023-41628-5","volume":"14","author":"F Hou","year":"2023","unstructured":"Hou F, Zhang Y, Liu X, Murad YM, Xu J, Yu Z, Hua X, Song Y, Ding J, Huang H, et al. mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge. Nat Commun. 2023;14:5925.","journal-title":"Nat Commun"},{"key":"4557_CR26","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1016\/j.cell.2024.08.043","volume":"187","author":"EM Mucker","year":"2024","unstructured":"Mucker EM, Freyn AW, Bixler SL, Cizmeci D, Atyeo C, Earl PL, Natarajan H, Santos G, Frey TR, Levin RH, et al. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell. 2024;187:5540\u2013e55535510.","journal-title":"Cell"},{"key":"4557_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","volume":"306","author":"JW Hooper","year":"2003","unstructured":"Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology. 2003;306:181\u201395.","journal-title":"Virology"},{"key":"4557_CR28","doi-asserted-by":"publisher","first-page":"e0150421","DOI":"10.1128\/JVI.01504-21","volume":"96","author":"EM Mucker","year":"2022","unstructured":"Mucker EM, Golden JW, Hammerbeck CD, Kishimori JM, Royals M, Joselyn MD, Ballantyne J, Nalca A, Hooper JW. A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge. J Virol. 2022;96:e0150421.","journal-title":"J Virol"},{"key":"4557_CR29","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.ymthe.2024.04.028","volume":"32","author":"J Zhou","year":"2024","unstructured":"Zhou J, Ye T, Yang Y, Li E, Zhang K, Wang Y, Chen S, Hu J, Zhang K, Liu F, et al. Circular RNA vaccines against monkeypox virus provide potent protection against vaccinia virus infection in mice. Mol Ther. 2024;32:1779\u201389.","journal-title":"Mol Ther"},{"key":"4557_CR30","doi-asserted-by":"publisher","first-page":"e70143","DOI":"10.1002\/jmv.70143","volume":"97","author":"X Chuai","year":"2025","unstructured":"Chuai X, Ye T, Zhao B, Wu Y, Guo C, Li F, Zhou J, Zhang K, Wang Y, Liu Y, et al. Long-Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice. J Med Virol. 2025;97:e70143.","journal-title":"J Med Virol"},{"key":"4557_CR31","doi-asserted-by":"publisher","first-page":"114269","DOI":"10.1016\/j.celrep.2024.114269","volume":"43","author":"T Ye","year":"2024","unstructured":"Ye T, Zhou J, Guo C, Zhang K, Wang Y, Liu Y, Zhou J, Xie Y, Li E, Gong R, et al. Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus. Cell Rep. 2024;43:114269.","journal-title":"Cell Rep"},{"key":"4557_CR32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schafer A, Ziwawo CT, DiPiazza AT, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567\u201371.","journal-title":"Nature"},{"key":"4557_CR33","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"4557_CR34","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41392-023-01574-6","volume":"8","author":"E Li","year":"2023","unstructured":"Li E, Guo X, Hong D, Gong Q, Xie W, Li T, Wang J, Chuai X, Chiu S. Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus. Signal Transduct Target Ther. 2023;8:350.","journal-title":"Signal Transduct Target Ther"},{"key":"4557_CR35","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1038\/s41467-025-58328-x","volume":"16","author":"W Tai","year":"2025","unstructured":"Tai W, Tian C, Shi H, Chai B, Yu X, Zhuang X, Dong P, Li M, Yin Q, Feng S, et al. An mRNA vaccine against monkeypox virus inhibits infection by co-activation of humoral and cellular immune responses. Nat Commun. 2025;16:2971.","journal-title":"Nat Commun"},{"key":"4557_CR36","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.4049\/jimmunol.172.10.6265","volume":"172","author":"R Xu","year":"2004","unstructured":"Xu R, Johnson AJ, Liggitt D, Bevan MJ. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol. 2004;172:6265\u201371.","journal-title":"J Immunol"},{"key":"4557_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/d41586-023-03058-7","volume":"622","author":"E Dolgin","year":"2023","unstructured":"Dolgin E. Why rings of RNA could be the next blockbuster drug. Nature. 2023;622:22\u20134.","journal-title":"Nature"},{"key":"4557_CR38","doi-asserted-by":"publisher","first-page":"e2302191120","DOI":"10.1073\/pnas.2302191120","volume":"120","author":"L Amaya","year":"2023","unstructured":"Amaya L, Grigoryan L, Li Z, Lee A, Wender PA, Pulendran B, Chang HY. Circular RNA vaccine induces potent T cell responses. Proc Natl Acad Sci U S A. 2023;120:e2302191120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4557_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41541-025-01097-x","volume":"10","author":"Z Gong","year":"2025","unstructured":"Gong Z, Hu W, Zhou C, Guo J, Yang L, Wang B. Recent advances and perspectives on the development of circular RNA cancer vaccines. NPJ Vaccines. 2025;10:41.","journal-title":"NPJ Vaccines"},{"key":"4557_CR40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","volume":"41","author":"R Chen","year":"2023","unstructured":"Chen R, Wang SK, Belk JA, Amaya L, Li Z, Cardenas A, Abe BT, Chen CK, Wender PA, Chang HY. Engineering circular RNA for enhanced protein production. Nat Biotechnol. 2023;41:262\u201372.","journal-title":"Nat Biotechnol"},{"key":"4557_CR41","doi-asserted-by":"crossref","unstructured":"Shen-Gunther J, Cai H, Wang Y. Genomic and Antigenic Differences Between Monkeypox Virus and Vaccinia Vaccines: Insights and Implications for Vaccinology. Int J Mol Sci. 2025;26:1428.","DOI":"10.3390\/ijms26041428"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04557-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04557-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04557-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:31:48Z","timestamp":1784766708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04557-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4557"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04557-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yun Yang, Jiang Hu, Kai Zhang and Fang Liu are employees of CirCode. Zefeng Wang is an advisor to CirCode. Zefeng Wang and Yun Yang are cofounders of CirCode Biomed. There is one unpublished patent application directed to the subject matter of the paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"695"}}